News & Insights News Events Insights Bulletin Subscribe

All Topics Health Technology Assessment (HTA) Antimicrobial Resistance (AMR) Subscribe

News & Insights News Events Insights Bulletin

Insight
11 min read 31st January 2024

Around The World in HTAs: Türkiye – The bumpy road toward

transformation
In this Insights series, Around the World in HTAs, we shed light on HTA around the world. In this
edition, Prof Hasan Huseyin Yildirim, Dilek Sernur Eminoğulları, Dr Tuba Saygın Avşar, and Patricia
Cubi-Molla take us to Türkiye.

Dr Tuba Saygın Avşar Professor Dr Hasan Hüseyin Yildirim

Dilek Sernur Eminoğulları Patricia Cubi-Molla

Share:  

Gizlilik - Şartlar
News & Insights News Events Insights Bulletin Subscribe

The health system in Türkiye

Over the last two decades, Türkiye (yes, this is the correct spelling!) has significantly improved
population health outcomes. For instance, the overall life expectancy reached 79 years in 2022 (it was
70 years in 2003), and the country achieved almost-universal health coverage through a universal
health insurance scheme, covering 99% of the population (up from 72% in 2003) (UN 2023, OECD
2023). However, the country continues to face issues related to health system resources, geographic
disparities, and emerging public health threats. Türkiye experiences a significant shortage of health
 workers, especially nurses and doctors. The uneven distribution of specialists exacerbates regional
News & Insights
disparities in access to healthcare. News Events Insights Bulletin Subscribe

The Turkish health system is highly consolidated under the Ministry of Health (MoH), which
implements policies set by the President (Polin et al. 2022). The service provision is dominated by
state-funded institutions, with the MoH overseeing most of the healthcare in the country. A family care
model has been implemented but there is no mandatory referral scheme to move from primary to
other levels of care. This puts a strain on the efficiency and quality of specialist services.

The country spends 4.7% of its GDP on healthcare, lower than the EU average (10.9%), while public
spending accounts for 78% of total health expenditure (WHO 2020). The Social Security Institution
(SSI) decides which services to be reimbursed under the universal health insurance scheme through
the Health Implementation Guide.

The HTA agency of Türkiye’s MoH was established in 2012 and was later re-named as Research
Development and Health Technology Assessment Department (HTAD). Additionally, the Turkish
Medicines and Medical Devices Agency (TMMDA) and the HTA department within SSI are the other
entities with the capability to produce national HTAs.

A roadmap for new technologies

In principle, a marketing authorisation obtained from the TMMDA is a prerequisite for entry into the
Turkish market. The SSI decides which health interventions will be reimbursed to whom, for how
much, and under what conditions. While fulfilling this function, the SSI has established the Healthcare
Services Pricing Commission (HSPC) which includes delegates of various Ministries. Each innovative
technology related to medicines is evaluated by one of the HSPC sub-commissions (either the Drug
Reimbursement Commission, or the Alternative Reimbursement Commission).

Considering that the entire pharmaceutical reimbursement system is based on mandatory discounts,
the Alternative Reimbursement Scheme (ARS) has been implemented since 2016, which has changed
the face of the system by allowing the use of innovative reimbursement models. These models are
mostly decided following negotiations on drug price, number of patients or total budget impact. ARS
has helped to mitigate problems associated with financial pressure on the pharmaceutical budget and
provided a good return to the pharmaceutical industry and the SSI so far.
 Another way to access the market is the Named Patient Program (NPP), which was formulated as an
News & Insights News Events Insights Bulletin Subscribe
exceptional way of reaching the market. Accordingly, medicines that the TMMDA has yet to authorise
or that cannot be obtained domestically, even if authorised, are imported from abroad for individual
use. The SSI manages this process based on the permission given by the TMMDA on an individual
basis. The introduction of new technologies has become more frequent in recent years and, as a
consequence, they may enter the market through the NPP. ARS conditions may also apply to imported
medicines for individual use.

Current challenges for HTA in Türkiye

Lack of transparency is perhaps the most significant challenge for HTA in Türkiye. In particular, there is
little opportunity for public scrutiny in the absence of a clear and transparent process (Ozturk et al.
2017). Even though there is a number of bodies conducting HTA, only the MoH publishes national HTA
reports. In addition, the topic selection processes for those HTAs have not been made publicly
available despite the Ministry’s Directive mandates.

There is no legal requirement for the SSI to conduct HTAs before making reimbursement decisions.
Thus, there is little incentive for allocating resources to HTA activities, which hinders the
comprehensive evaluation of health technologies, restricting the scope and depth of assessments. On
top of that, the fragmented structure of HTA bodies and lack of coordination between HTA authorities
is a barrier to the efficient use of limited capacity.

Türkiye does not have standardised methodologies and clear guidelines for conducting HTA, which
leads to discrepancies in assessment processes and outcomes, affecting the consistency and
comparability of results (Avşar and Yıldırım 2023). Recently, the CHEERs reporting guidelines for
economic evaluation studies were adapted to Turkish, which might be helpful for the economic
evaluation component of HTAs.

Next steps for HTA in Türkiye

According to Castro et al.’s (2020) HTA framework, Türkiye is at the policy formulation stage, with
sporadic HTA activities taking place in different organisations. HTA in Türkiye has been waiting for the
legal regulations and formalisation of HTA for over a decade.
 The Smart Life and Health Products and Technologies Roadmap (you can access here), published by
News & Insights News Events Insights Bulletin Subscribe
the Ministry of Industry and Technology, proposes the establishment of a politically independent
national HTA institution between 2022 and 2025. This institution would provide objective scientific
advice, like NICE in the UK. This is promising but political will is required to determine the role of HTA
in reimbursement decisions.

After the establishment of an independent HTA body, an important step is to create national HTA
guidelines to produce consistent and useful HTA evidence that can inform policy. Related to this,
some experts believe the country should adopt a cost-effectiveness threshold (Atikeler 2023) – but
further discussions and empirical research about the potential implications of setting a threshold are
needed.

In terms of expertise in HTA methodologies, the country has an emerging capacity in health
economics; however, training and development programs for HTA professionals are essential to
improve the quality and reliability of assessments (Gheorge et al. 2020). Collaboration with established
HTA agencies, such as NICE, could be beneficial.

With the promise of national guidelines, consideration of cost-effectiveness thresholds, and ongoing
capacity-building efforts, Türkiye is poised for a transformative leap. The convergence of political
commitment, national guidelines, stakeholder engagement, and enhanced public awareness holds the
key to unlocking a future where evidence-based decision-making becomes the cornerstone of
healthcare resource allocation.

Insight April 2023

Around The World in

HTAs: Italy – What’s
Next?
 Read more
News & Insights News Events Insights Bulletin Subscribe

Health Technology Assessment… Value, Affordability, and… Around the World in HTAs

Back

Related Insights

Insight January 2024

Insight February 2024 Insight October 2023 Insight September 2023

Navigating the
Intersection of
Looking further afield – Healthcare and Around The World in Around The World in
What can health Environmental HTAs: Greece – Late HTAs: The Slovak
economics learn from Sustainability: ISPOR but with an Optimistic Republic – Valuing the
the environmental Europe round-up on the Future Future
economics approach to inclusion of
discounting?
 environmental impact
News & Insights
Read more in HTA News Events Insights Bulletin
Read more Read more
Subscribe

Read more

Leading intellectual authority on global health economics Research & Publications Events

News & Insights About Us

Sign Up for OHE Insights, Events & News Bulletin Innovation Policy Prize OHE Experts

Start Sign Up Education Contact Us

 

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales
(registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, Terms & Conditions Privacy Policy Cookies Policy © 2024 Website Design
London, SE1 2HB.